Compare CPS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPS | CTMX |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | CPS | CTMX |
|---|---|---|
| Price | $33.66 | $4.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $26.50 | $6.50 |
| AVG Volume (30 Days) | 147.3K | ★ 2.1M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | ★ 1.84 | 0.24 |
| Revenue | ★ $2,729,297,000.00 | $113,631,000.00 |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $6.65 | N/A |
| P/E Ratio | $17.90 | ★ $17.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.38 | $0.40 |
| 52 Week High | $40.67 | $4.62 |
| Indicator | CPS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 56.75 |
| Support Level | $29.67 | $3.78 |
| Resistance Level | $30.70 | $4.20 |
| Average True Range (ATR) | 1.08 | 0.23 |
| MACD | 0.48 | -0.01 |
| Stochastic Oscillator | 81.03 | 72.39 |
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.